Last updated: 3 July 2019 at 3:50am EST

Alvin S Parven Net Worth




The estimated Net Worth of Alvin S Parven is at least $8.95 Million dollars as of 15 June 2017. Alvin Parven owns over 835 units of Alexion Pharmaceuticals stock worth over $1,385,549 and over the last 21 years Alvin sold ALXN stock worth over $7,564,112.

Alvin Parven ALXN stock SEC Form 4 insiders trading

Alvin has made over 29 trades of the Alexion Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Alvin sold 835 units of ALXN stock worth $97,511 on 15 June 2017.

The largest trade Alvin's ever made was exercising 30,000 units of Alexion Pharmaceuticals stock on 19 November 2012 worth over $325,200. On average, Alvin trades about 5,491 units every 84 days since 2003. As of 15 June 2017 Alvin still owns at least 7,568 units of Alexion Pharmaceuticals stock.

You can see the complete history of Alvin Parven stock trades at the bottom of the page.



What's Alvin Parven's mailing address?

Alvin's mailing address filed with the SEC is C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE, CT, 06410.

Insiders trading at Alexion Pharmaceuticals

Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell, and Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.



What does Alexion Pharmaceuticals do?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



Complete history of Alvin Parven stock trades at Alexion Pharmaceuticals

Insider
Trans.
Transaction
Total value
Alvin S Parven
Director
Sale $97,511
15 Jun 2017
Alvin S Parven
Director
Sale $3,134,873
5 Jan 2017
Alvin S Parven
Director
Sale $2,142,736
15 Aug 2016
Alvin S Parven
Director
Sale $159,963
2 Nov 2015
Alvin S Parven
Director
Option $270,150
11 Nov 2014
Alvin S Parven
Director
Option $206,605
13 May 2014
Alvin S Parven
Director
Sale $430,102
11 Feb 2014
Alvin S Parven
Director
Sale $286,580
8 Mar 2013
Alvin S Parven
Director
Option $325,200
19 Nov 2012
Alvin S Parven
Director
Option $245,400
8 Jun 2012
Alvin S Parven
Director
Buy $11,893
5 Mar 2012
Alvin S Parven
Director
Sale $444,230
21 Feb 2012
Alvin S Parven
Director
Option $245,711
3 Feb 2012
Alvin S Parven
Director
Option $31,375
31 Oct 2011
Alvin S Parven
Director
Sale $366,564
17 Feb 2011
Alvin S Parven
Director
Option $116,249
2 Feb 2011
Alvin S Parven
Director
Option $116,644
9 Nov 2010
Alvin S Parven
Director
Option $42,960
31 Aug 2010
Alvin S Parven
Director
Sale $247,733
18 Feb 2010
Alvin S Parven
Director
Option $90,799
28 Jan 2010
Alvin S Parven
Director
Option $294,600
11 Dec 2009
Alvin S Parven
Director
Option $116,850
27 Jul 2009
Alvin S Parven
Director
Sale $131,120
10 Mar 2009
Alvin S Parven
Director
Option $772,255
5 Aug 2008
Alvin S Parven
Director
Option $141,440
4 Jun 2008
Alvin S Parven
Director
Sale $122,700
22 Feb 2008
Alvin S Parven
Director
Option $1,736,900
29 Oct 2007
Alvin S Parven
Director
Option $245,696
3 Nov 2006
Alvin S Parven
Director
Buy $28,050
13 Oct 2005


Alexion Pharmaceuticals executives and stock owners

Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: